Remove Development Remove Drug Delivery Remove Insulin Remove Marketing
article thumbnail

Oramed inks deal to commercialize oral insulin in South Korea

BioPharma Reporter

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 96
article thumbnail

Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market

XTalks

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections.

Insulin 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Injectable Drug Delivery 2022

pharmaphorum

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.

article thumbnail

Phase 3 trial dashes Oramed’s oral insulin hopes

pharmaphorum

Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.

Insulin 59
article thumbnail

In the News: September Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA has also recently launched the Software Pre-Certification Pilot Program to provide an efficient regulatory framework for developers of SaMD products.

article thumbnail

Patient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet Micron

XTalks

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Traditional needles on the market range between 8 and 12.5

Insulin 64
article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades.